Guideline

Updated recommendations on treatment of adolescents and children with chronic HCV infection: policy brief.

Year of Publication

2022

Issuing Institution

World Health Organization

Links

WHO IRIS

Recommendations

12 included recommendations

We recommend treatment using pangenotypic direct-acting antiviral (DAA) regimens for all adults with chronic hepatitis C infection, regardless of stage of disease

Status

Maintained

Recommended in favor

Strong

Certainty of evidence

Moderate

We recommend treatment using pangenotypic DAA regimens for all adolescents (12–17 years) with chronic hepatitis C infection, regardless of stage of disease

Status

Maintained

Recommended in favor

Strong

Certainty of evidence

Low

We recommend treatment using pangenotypic DAA regimens for all children ages 6–11 years with chronic hepatitis C infection, regardless of stage of disease

Status

Maintained

Recommended in favor

Strong

Certainty of evidence

Very low

We recommend treatment using pangenotypic DAA regimens for all children ages 3–5 years years with chronic hepatitis C infection, regardless of stage of disease

Status

Maintained

Recommended in favor

Conditional

Certainty of evidence

Very low

We recommend the use of the following pangenotypic DAA regimens in adults (18 years and above) with chronic hepatitis C infection, regardless of stage of disease: sofosbuvir/daclatasvir (Most widely used regimen in adults due to availability of quality-assured, low-cost generics) for 12 weeks (In those without cirrhosis. Treatment for 24 weeks in those who are treatment-experienced or with compensated cirrhosis), sofosbuvir/velpatasvir for 12 weeks, glecaprevir/pibrentasvir for eight weeks

Status

Maintained

Recommended in favor

Strong

Certainty of evidence

High

We recommend the use of the following pangenotypic DAA regimens in adolescents (12–17 years) with chronic hepatitis C infection, regardless of stage of disease: sofosbuvir/daclatasvir (Most widely used regimen in adults due to availability of quality-assured, low-cost generics) for 12 weeks (In those without cirrhosis. Treatment for 24 weeks in those who are treatment-experienced or with compensated cirrhosis)

Status

Maintained

Recommended in favor

Strong

Certainty of evidence

High

We recommend the use of the following pangenotypic DAA regimens in adolescents (12–17 years) with chronic hepatitis C infection, regardless of stage of disease: sofosbuvir/velpatasvir for 12 weeks

Status

Maintained

Recommended in favor

Strong

Certainty of evidence

Low

We recommend the use of the following pangenotypic DAA regimens in adolescents (12–17 years) with chronic hepatitis C infection, regardless of stage of disease: glecaprevir/pibrentasvir for eight weeks

Status

Maintained

Recommended in favor

Strong

Certainty of evidence

Moderate

We recommend the use of the following pangenotypic DAA regimens in older children (6–11 years) with chronic hepatitis C infection, regardless of stage of disease: sofosbuvir/daclatasvir (Most widely used regimen in adults due to availability of quality-assured, low-cost generics) for 12 weeks (In those without cirrhosis. Treatment for 24 weeks in those who are treatment-experienced or with compensated cirrhosis)

Status

Maintained

Recommended in favor

Strong

Certainty of evidence

High

We recommend the use of the following pangenotypic DAA regimens in older children (6–11 years) with chronic hepatitis C infection, regardless of stage of disease: sofosbuvir/velpatasvir for 12 weeks

Status

Maintained

Recommended in favor

Strong

Certainty of evidence

Low

We recommend the use of the following pangenotypic DAA regimens in older children (6–11 years) with chronic hepatitis C infection, regardless of stage of disease: glecaprevir/pibrentasvir for eight weeks

Status

Maintained

Recommended in favor

Strong

Certainty of evidence

Moderate

We recommend the use of the following pangenotypic DAA regimens in younger children (3–5 years) with chronic hepatitis C infection, regardless of stage of disease: sofosbuvir/daclatasvir (Most widely used regimen in adults due to availability of quality-assured, low-cost generics) for 12 weeks (In those without cirrhosis. Treatment for 24 weeks in those who are treatment-experienced or with compensated cirrhosis), sofosbuvir/velpatasvir for 12 weeks, glecaprevir/pibrentasvir for eight weeks

Status

Maintained

Recommended in favor

Conditional

Certainty of evidence

Very low